Biosyent Inc

Biosyent Inc company information, Employees & Contact Information

Updated May 2026

Quick answer

Biosyent Inc is a Pharmaceutical Manufacturing company. It has approximately 71 employees on record. Contact data was last refreshed in May 2026. Find Biosyent Inc's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Listed on the TSX Venture Exchange (TSXV: RX) BioSyent is a profitable growth oriented speciality pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada. BioSyent continues to search for products to in-license or acquire that match the following criteria: - Are unique and occupy a niche in the market; - Provide novel technological or therapeutic advantages to patients and healthcare professionals; - Are backed by strong partners who hold defendable intellectual property rights. Backed by the success of our products, for two consecutive years (2012 & 2013) BioSyent was named to the TSX Venture Top 50 strong performing companies. BioSyent has been named one of Canada’s fastest growing companies by PROFIT Magazine.

Company Details

Employees
71
Phone
905.206.0013
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Looking for a particular Biosyent Inc employee's phone or email?

Biosyent Inc Questions

News

BioSyent Releases Financial Results for Q2 and H1 2025 - GlobeNewswire

BioSyent Releases Financial Results for Q2 and H1 2025 GlobeNewswire

BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025 - Investing News Network

BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025 Investing News Network

BioSyent Declares Third Quarter 2025 Dividend - The Globe and Mail

BioSyent Declares Third Quarter 2025 Dividend The Globe and Mail

BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets - Yahoo Finance

BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets Yahoo Finance

BioSyent Announces Renewal of Normal Course Issuer Bid - GlobeNewswire

BioSyent Announces Renewal of Normal Course Issuer Bid GlobeNewswire

BioSyent Releases Financial Results for Q2 and H1 2024 - Yahoo Finance

BioSyent Releases Financial Results for Q2 and H1 2024 Yahoo Finance

FeraMAX® Named #1 Recommended Iron Supplement in Canada by - GlobeNewswire

FeraMAX® Named #1 Recommended Iron Supplement in Canada by GlobeNewswire

BioSyent to Attend Planet MicroCap Showcase - GlobeNewswire

BioSyent to Attend Planet MicroCap Showcase GlobeNewswire

BioSyent Announces Launch of New FeraMAX® Pd Powder 15 - GlobeNewswire

BioSyent Announces Launch of New FeraMAX® Pd Powder 15 GlobeNewswire

Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150 - GlobeNewswire

Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150 GlobeNewswire

Top Biosyent Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant